Frequently Asked Questions
The market is segmented based on , By Product (Consumables, Services, Software, Growth Hormone Therapy), Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Protein Biomarkers, Pharmacodynamics Biomarkers, Genetic Biomarkers), Profiling Technologies (OMICS, Imaging Technology, Immunoassays, Cytogenetics and Bioinformatics), Service (Sample Preparation, Assay Development, Biomarkers and Testing), Application (Diagnostics Development, Drug Discovery and Development, Personalized Medicine, Disease-Risk Assessment, Others), Disease (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Other Diseases), Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Others) – Industry Trends and Forecast to 2030.
.
The Europe Cancer Biomarkers Market size was valued at USD 4.15 USD Billion in 2022.
The Europe Cancer Biomarkers Market is projected to grow at a CAGR of 11% during the forecast period of 2023 to 2030.
The major players operating in the market include F. Hoffmann-La Roche , Thermo Fisher Scientific , Abbott, QIAGEN, PerkinElmer , Merck KGaA, Bio-Rad Laboratories , Enzo Biochem , Charles River Laboratories, Eurofins Scientific, Agilent Technologies , Bruker, Siemens, Epigenomics AG, General Electric
.
The market report covers data from the Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
